BPR 277

Drug Profile

BPR 277

Alternative Names: BPR277

Latest Information Update: 24 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Skin disorder therapies
  • Mechanism of Action Kallikrein-related peptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Atopic dermatitis; Congenital ichthyosiform erythroderma

Most Recent Events

  • 25 Jan 2016 No recent reports on development identified - Phase-I/II for Atopic dermatitis in USA, Germany and Netherlands (Topical)
  • 25 Jan 2016 No recent reports on development identified - Phase-I/II for Congenital ichthyosiform erythroderma in USA, Germany and the Netherlands (Topical)
  • 01 Feb 2014 Novartis completes a phase I/II trial in Atopic dermatitis and Congenital ichthyosiform erythroderma in USA and Netherlands (NCT01428297)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top